Pharmaceuticals News

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today...

Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position with...

AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarterContinued growth expectations drive Q4 2026 net product revenue guidance of...

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis,...

VALNEVA Declaration of shares and voting rights Status as of October 31, 2026__________________________________________________________________________________________ Company name:...

VALNEVA Déclaration d’actions et de droits de vote Statut au 31 octobre 2026__________________________________________________________________________________________ Dénomination sociale :...

Bagsværd, Denmark, 3 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...

T-Cypher Bio Presents Promising Data on Two T Cell Engager Development Candidates for High Copy Number Cancer Targets at the 2026 Society for Immunotherapy

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, a clinical-stage biotech company harnessing the power of the innate and adaptive immune systems, today announced that two...

New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio...